Protective effects of Zeolive in Lead poisoning

Phase 1

Recruiting

Conditions: ead poisoning.
Poisoning by and exposure to nonopioid analgesics, antipyretics and antirheumatics, undetermined intent

Registration Number: IRCT20211213053375N2

Lead Sponsor: Toxicological Research Center

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 80

Inclusion Criteria

Serum Lead level between 20 and 60 µg/dL.
Not having severe clinical symptoms of Lead poisoning and as a result no need to prescribe standard chelators.
Patients who had informed consent to participate in the study.

Exclusion Criteria

Allergic reaction to zeolite compounds.
Previous receipt of chelator drugs that are routinely prescribed in the standard treatment of Lead poisoning.
Patients with any kinds of underlying disease including hepatic disorder, diabetes, heart failure, renal failure.

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
ormal serum level of Lead. Timepoint: The serum levels of Lead will be measured before the administration of Zeolive and 14 days after the start of its administration. Method of measurement: Serum levels of Lead will be measured using the COBAS-INTEGRA 400 Plus.

Secondary Outcome Measures

Name	Time	Method
Complete blood count (CBC). Timepoint: Complete blood count (CBC) will be counted at the beginning of the study (before Zeolive administration) and 14 days after its administration. Method of measurement: Complete blood count will be measured using the Sysmex-KX-21.;Serum electrolyte measurement. Timepoint: Serum electrolytes will be measured at the beginning of the study (before Zeolive administration) and 14 days after its administration. Method of measurement: Serum electrolyte measurement will be done using Medica-EasyLyte.;Measurement of Creatinine and Blood Urea Nitrogen levels. Timepoint: Creatinine and Blood Urea Nitrogen levels will be measured at the beginning of the study (before Zeolive administration) and 14 days after its administration. Method of measurement: Creatinine and Blood Urea Nitrogen levels will be measured using the Mindray BS-800.